Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
NPJ Vaccines|June 28, 2024
Myocarditis associated with COVID-19 vaccinationAlessandra Buoninfante, Arno Andeweg, Georgy Genov, et al.
Drug Safety|July 24, 2017
Promoting and Protecting Public Health: How the European Union Pharmacovigilance System WorksAniello Santoro, Georgy Genov, Almath Spooner, et al.
Clinical Pharmacology and Therapeutics|October 18, 2019
Improving the Safety of Medicines in the European Union: From Signals to ActionJoanne Potts, Georgy Genov, Andrej Segec, et al.
Drug Safety|April 19, 2017
Patient Reporting in the EU: Analysis of EudraVigilance DataMarin Banovac, Gianmario Candore, Jim Slattery, et al.
Pharmacoepidemiology and Drug Safety|October 25, 2020
What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?Justina Januskiene, Andrej Segec, Jim Slattery, et al.
Drug Safety|April 12, 2024
COVID-19 Vaccines and Heavy Menstrual Bleeding: The Impact of Media Attention on Reporting to EudraVigilanceMaría Gordillo-Marañón, Agnieszka Szmigiel, Vladimíra Yalmanová, et al.
Clinical Pharmacology and Therapeutics|December 16, 2022
Safety Monitoring of COVID-19 Vaccines: Perspective from the European Medicines AgencyJulie Durand, Jean-Michel Dogné, Catherine Cohet, et al.
Drug Safety|July 10, 2024
The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU SystemPriya Bahri, Georgy Genov, Peter Arlett, et al.
Drug Safety|November 16, 2014
A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committeeAlexandra C Pacurariu, Preciosa M Coloma, Anja van Haren, et al.
Pharmacoepidemiology and Drug Safety|December 27, 2017
Is patient exposure preapproval and postapproval a determinant of the timing and frequency of occurrence of safety issues?Alexandra C Pacurariu, Christina E Hoeve, Peter Arlett, et al.
Pageof 2